BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma

Written By Team Rxtrospect
Team Rxtrospect
Previous

Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
Next

FDA accelerated approval for zanidatamab in previously treated, unresectable or metastatic HER2-positive (IHC 3+) Biliary Tract Cancer